CN105997921A - Diclofenac potassium effervescent tablet for pets and preparation method of diclofenac potassium effervescent tablet - Google Patents
Diclofenac potassium effervescent tablet for pets and preparation method of diclofenac potassium effervescent tablet Download PDFInfo
- Publication number
- CN105997921A CN105997921A CN201610361323.2A CN201610361323A CN105997921A CN 105997921 A CN105997921 A CN 105997921A CN 201610361323 A CN201610361323 A CN 201610361323A CN 105997921 A CN105997921 A CN 105997921A
- Authority
- CN
- China
- Prior art keywords
- diclofenac potassium
- effervescent tablet
- potassium
- house pet
- polyvidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Abstract
The invention provides a diclofenac potassium effervescent tablet for pets. The diclofenac potassium effervescent tablet is prepared from the following components by weight: 5-15% of diclofenac potassium, 10-30% of tartaric acid, 10-30% of sodium bicarbonate, 1-15% of povidone, 1-15% of polyethylene glycol 6000, 10-25% of mannitol, 10-25% of lactose and 0.01-3% of magnesium stearate. The invention further provides a preparation method of the diclofenac potassium effervescent tablet. The diclofenac potassium effervescent tablet contains the antipyretic-analgesic and anti-inflammatory drug with good curative effect, high efficiency, less side effects and taking convenience, can quickly and remarkably relieve such symptoms as high fever, inflammation, pain and seizure of the pets, caused by various reasons, guarantees the health of the pets and enables harmony between mankind and the pets.
Description
Technical field
The invention belongs to veterinary medicine technical field, in particular it relates to a kind of diclofenac potassium for house pet antipyretic-antalgic
Effervescent tablet and preparation method thereof.
Background technology
Constantly improve along with people's living standard, reducing of household size, pet feeding have become as more and more all
A part for people from city life, in the urgent need to strengthening house pet social management and Medical pet health care.As animal, house pet is sick in institute
Unavoidably, Canis familiaris L., cat etc. can be promoted to dote on due to parasite and pathogenic infection, the sultry humidity of weather, skin injury and having a delicate constitution etc.
Thing heatstroke, suffer from the febrile diseases such as tracheitis, pleuropneumonia, gingivitis, respiratory infectious disease, to house pet and the body and mind of owner
Health all damages；And some house pet owing to spraining, infecting, heredity, movement transitions, the reason such as overweight suffer from infectious joint
Inflammation, prolapse of lumbar intervertebral disc (waist disease, lumbar spondylosis), dog DCM (dilated cardiomyopathy) enteritis, peritonitis, rickets, osteoarthritis, fracture,
Dislocation of hip joint, rheumatoid arthritis, periarticular soft tissues inflammation and damage caused by arthralgia and Post operation pain
The various acute pains such as pain make house pet hyperpyrexia, are slow in action, and become drowsiness, dejected or temper and degenerate, and appetite has declined
Or food is lost interest in, serious symptom person causes death.
Diclofenac potassium is the potent non_steroidal anti_inflammatory drug of the third generation, can effectively alleviate the hyperpyrexia that various factors causes
Shape.Its curative effect is better than other outer steroids anti-class medicines such as indometacin, aspirin, ibuprofen, naproxen, also has and thinks this medicine town
Effect bitterly is better than current all anti-inflammation and analgesic drugs.Existing diclofenac potassium medicament mostly is conventional tablet or slow releasing tablet, and
There is the problems such as relatively slow, side effect is relatively big, medication inconvenience that take effect.
Summary of the invention
In view of this, the present invention provides a kind of for house pet diclofenac potassium effervescent tablet and preparation method thereof, to solve
The problems referred to above.
Specifically, the present invention adopts the following technical scheme that:
A kind of house pet diclofenac potassium effervescent tablet, wherein, it includes following components in percentage by weight: diclofenac potassium 5%～
15%, tartaric acid 10%～30%, sodium bicarbonate 10%～30%, polyvidone 1%～15%, polyethylene glycol 6000 1%～15%, mannitol
10%～25%, lactose 10%～25%, magnesium stearate 0.01%～3%.
Based on above-mentioned house pet diclofenac potassium effervescent tablet, it includes following components in percentage by weight: diclofenac potassium
8%～10%, tartaric acid 15%～25%, sodium bicarbonate 15%～25%, polyvidone 5%～10%, polyethylene glycol 6000 5%～10%, sweet
Dew alcohol 15%～20%, lactose 15%～20%, magnesium stearate 0.05%～2%.
Based on above-mentioned house pet diclofenac potassium effervescent tablet, it includes following components in percentage by weight: diclofenac potassium
10%, tartaric acid 20%, sodium bicarbonate 20%, polyvidone 7%, polyethylene glycol 6000 7%, mannitol 15%, lactose 20%, magnesium stearate
1%。
Wherein, described house pet with in diclofenac potassium effervescent tablet, tartaric acid is used as the acid source of effervescent tablet；Sodium bicarbonate is used
Making the alkali source of effervescent tablet, tartaric acid generates carbon dioxide with reaction of sodium bicarbonate, produces effervescent effect；Polyvidone is used as bonding
Agent；Polyethylene glycol 6000 not only has good moisture-resisting, lubrication, also has dry adhesive, the effect of rush disintegrate, can make tablet
Surface is glossy and smooth, be hardly damaged simultaneously；Mannitol is used as filler with lactose；Magnesium stearate is used as lubricant.
A kind of above-mentioned house pet preparation method of diclofenac potassium effervescent tablet, step is as described below:
Diclofenac potassium, tartaric acid, sodium bicarbonate, polyethylene glycol 6000, mannitol, lactose are crossed respectively 80 mesh sieves, then presses
Uniformly mix according to above-mentioned percentage by weight, form mixture of powders；
Polyvidone is dissolved in the ethanol solution that concentration is 95% formation polyvidone ethanol solution, is the most uniformly sprayed onto described
Mixture of powders is made soft material；
Described soft material is carried out pelletize process, obtains soft material granule；At 40～50 DEG C, described soft material granule is carried out drying and processing,
It is then passed through 16 mesh sieves and granulate processes, obtain the soft material granule after granulate；
Soft material granule after described granulate adds magnesium stearate, and uniformly mixes, be then placed in tabletted in tablet machine,
Obtain described diclofenac potassium effervescent tablet.
Compared with prior art, it is rapid that the described diclofenac potassium effervescent tablet that the present invention provides mainly has disintegrate, can fill
The antipyretic and anti-inflammatory analgesic activity of diclofenac potassium, the discomfort of rapid recovery house pet are waved in distribution, and bioavailability is high, saves for consumer
Save the advantages such as spending；Additionally, the described diclofenac potassium effervescent tablet that the present invention provides is a kind of house pet antipyretic-antalgic medication brand-new
Agent, also has advantages such as carrying, easy to use, effective, instant effect, stability are strong.It addition, the described pair of chlorine that the present invention provides
The preparation technology of fragrant acid potassium effervescent tablet is simple, facilitates commercial production, for a kind of alternative antiinflammatory town of the many offers of pet care
Medicine bitterly.Therefore, the described diclofenac potassium effervescent tablet that the present invention provides has good effect, instant effect, side effect is little, use prescription
Just antipyretic and anti-inflammatory analgesic, it is possible to quickly alleviate significantly the high heat caused by house pet a variety of causes, inflammation, pain symptom and
The symptom of outbreak, it is ensured that the health of house pet, makes people get along amiably and peacefully with house pet.
Detailed description of the invention
Below by detailed description of the invention, technical scheme is described in further detail.
Embodiment 1
The present embodiment house pet diclofenac potassium effervescent tablet, including following components in percentage by weight: (by 1000 diclofenacs
Potassium effervescent tablet supplementary material proportioning, monolithic weight 0.3g):
Diclofenac potassium 15 g
Tartaric acid 45 g
Sodium bicarbonate 45 g
Polyvidone 45 g
Polyethylene glycol 6000 45 g
Mannitol 45 g
Lactose 59.95 g
Magnesium stearate 0.05 g
Concrete preparation process is:
(1) by diclofenac potassium, tartaric acid, sodium bicarbonate, polyethylene glycol 6000, mannitol, lactose, 80 mesh sieves are crossed, standby；
(2) each component in step (1) is weighed according to the weight of the present embodiment, mixing, form mixture of powders；
(3) polyvidone is dissolved in the ethanol solution that concentration is 95%, mix homogeneously, standby；
(4) in mixture of powders, uniformly spray polyvidone ethanol solution, make soft material；
(5) soft material is added granulator and by the granule that makes 40 DEG C of drying；
(6) 16 mesh sieves are crossed, granulate, add magnesium stearate, mixing；
(7) tablet machine is put into, tabletted, obtain diclofenac potassium effervescent tablet.
Embodiment 2
The present embodiment house pet diclofenac potassium effervescent tablet, including following components in percentage by weight: (by 1000 diclofenacs
Potassium effervescent tablet supplementary material proportioning, monolithic weighs 0.3 g):
Diclofenac potassium 24 g
Tartaric acid 45 g
Sodium bicarbonate 60 g
Polyvidone 30 g
Polyethylene glycol 6000 20 g
Mannitol 74.5 g
Lactose 45 g
Magnesium stearate 1.5 g
The house pet that the present embodiment provides is used double with the house pet that the concrete preparation method of diclofenac potassium effervescent tablet and embodiment 1 provide
The preparation method of chlorine sweet smell acid potassium effervescent tablet is essentially identical, and difference is: the house pet that in the present embodiment, step (2) weighs is with double
The weight of the component of chlorine sweet smell acid potassium effervescent tablet is different from embodiment 1；The drying temperature used in step (5) is 50 DEG C.
Embodiment 3
The present embodiment house pet diclofenac potassium effervescent tablet, including following components in percentage by weight: (by 1000 diclofenacs
Potassium effervescent tablet supplementary material proportioning, monolithic weighs 0.3 g):
Diclofenac potassium 30 g
Tartaric acid 60 g
Sodium bicarbonate 60 g
Polyvidone 21g
Polyethylene glycol 6000 21g
Mannitol 45 g
Lactose 60 g
Magnesium stearate 3 g
The house pet that the present embodiment provides is used double with the house pet that the concrete preparation method of diclofenac potassium effervescent tablet and embodiment 1 provide
The preparation method of chlorine sweet smell acid potassium effervescent tablet is essentially identical, and difference is: the house pet that in the present embodiment, step (2) weighs is with double
The weight of the component of chlorine sweet smell acid potassium effervescent tablet is different from embodiment 1；The drying temperature used in step (5) is 45 DEG C.
Embodiment 4
The present embodiment house pet diclofenac potassium effervescent tablet, including following components in percentage by weight: (by 1000 diclofenacs
Potassium effervescent tablet supplementary material proportioning, monolithic weighs 0.3 g):
Diclofenac potassium 40 g
Tartaric acid 50 g
Sodium bicarbonate 70 g
Polyvidone 24 g
Polyethylene glycol 6000 15 g
Mannitol 54 g
Lactose 41 g
Magnesium stearate 6 g
The house pet that the present embodiment provides is used double with the house pet that the concrete preparation method of diclofenac potassium effervescent tablet and embodiment 1 provide
The preparation method of chlorine sweet smell acid potassium effervescent tablet is essentially identical, and difference is: the house pet that in the present embodiment, step (2) weighs is with double
The weight of the component of chlorine sweet smell acid potassium effervescent tablet is different from embodiment 1；The drying temperature used in step (5) is 43 DEG C.
Embodiment 5
The present embodiment house pet diclofenac potassium effervescent tablet, including following components in percentage by weight: (by 1000 diclofenacs
Potassium effervescent tablet supplementary material proportioning, monolithic weighs 0.3 g):
Diclofenac potassium 45 g
Tartaric acid 35 g
Sodium bicarbonate 90 g
Polyvidone 15 g
Polyethylene glycol 6000 6 g
Mannitol 50 g
Lactose 50 g
Magnesium stearate 9 g
The house pet that the present embodiment provides is used double with the house pet that the concrete preparation method of diclofenac potassium effervescent tablet and embodiment 1 provide
The preparation method of chlorine sweet smell acid potassium effervescent tablet is essentially identical, and difference is: the house pet that in the present embodiment, step (2) weighs is with double
The weight of the component of chlorine sweet smell acid potassium effervescent tablet is different from embodiment 1；The drying temperature used in step (5) is 45 DEG C.
Test disintegration of effervescent tablet
The house pet preparing embodiment 1～5 was tested with the disintegration of diclofenac potassium effervescent tablet: Example 1～5 is made
Each 10 of effervescent tablet disintegration of the above-mentioned effervescent tablet obtained, uses lift disintegration tester, according to Chinese Pharmacopoeia version two in 2010
The regulation in portion is carried out, and carries out inspection disintegration under the conditions of room temperature (23 DEG C).
Check result: all effervescent tablets are all 4 points of disintegrates within 10 seconds；The effervescent tablet of disintegrate in 2～4 minutes is more than 90%.
The therapeutic effect of pet dog osteoarthritis is detected by diclofenac potassium effervescent tablet
Experimental animal: 70 ill pet dogs (Zhengzhou, henan Animal Shelter institute), symptomatic diagnosis suffers from osteoarthritis.
Diagnostic criteria: body temperature is increased to more than 39 DEG C, movable minimizing, to take a walk and often fall behind, weigh row in the hand, movable posterior joint is stiff
Firmly, dysstasia, arthroncus, touching site of pathological change can bark because of pain or whine.
Test packet and process: 70 ill pet dogs are divided into 7 groups, test group 1～5, diclofenac potassium conventional tablet group
(diclofenac potassium conventional tablet is purchased from Zhengzhou veterinary drug company limited) and negative control group, often group 10.Test group 1～5 depends on
The diclofenac potassium effervescent tablet of secondary employing embodiment 1～5 preparation is treated, and 0.3 gram/times (with diclofenac potassium effective content
Meter), every day 2 times, for oral administration, it is used in conjunction 1 week；Diclofenac potassium conventional tablet group (in terms of diclofenac potassium effective content) 0.3 gram/
Secondary, every day 2 times, for oral administration, it is used in conjunction 1 week；Negative control group is not administered process.
Test method: above each group carries out body temperature measurement at 0 d, 1d, 3 d, 5 d, 7 d after being administered respectively, observes antipyretic
Anti-inflammatory pain-stopping effect, result see table 1.
The zooperal clinical treatment outcome of table 1
Result shows: diclofenac potassium effervescent tablet is that visible ill pet dog body temperature is decreased obviously after a procedure after 3 days, medication 5
After it, body temperature recovers normal substantially, and medication is walked after 1 week and recovered normal, and arthroncus disappears, and presses without pain reaction, antiinflammatory town
Effect bitterly is notable, and compared with diclofenac potassium conventional tablet, diclofenac potassium Effervescent tablet disintegration prepared by the present invention is fast, absorbs
Hurry up, bioavailability is high so that it is can quickly give full play to medicament usefulness.
Finally should be noted that: above example is only in order to illustrate that technical scheme is not intended to limit；To the greatest extent
The present invention has been described in detail by pipe with reference to preferred embodiment, and those of ordinary skill in the field are it is understood that still
The detailed description of the invention of the present invention can be modified or portion of techniques feature is carried out equivalent；Without deviating from this
The spirit of bright technical scheme, it all should be contained in the middle of the technical scheme scope that the present invention is claimed.
Claims (4)
1. a house pet diclofenac potassium effervescent tablet, it is characterised in that it includes following components in percentage by weight: double chlorine are fragrant
Acid potassium 5%～15%, tartaric acid 10%～30%, sodium bicarbonate 10%～30%, polyvidone 1%～15%, polyethylene glycol 6000 1%～
15%, mannitol 10%～25%, lactose 10%～25%, magnesium stearate 0.01%～3%.
House pet the most according to claim 1 diclofenac potassium effervescent tablet, it is characterised in that it includes following weight percent
The component of ratio: diclofenac potassium 8%～15%, tartaric acid 15%～30%, sodium bicarbonate 15%～30%, polyvidone 5%～15%, poly-second
Glycol 6,000 5%～15%, mannitol 15%～25%, lactose 15%～25%, magnesium stearate 0.05%～2%.
House pet the most according to claim 1 diclofenac potassium effervescent tablet, it is characterised in that it includes following weight percent
The component of ratio: diclofenac potassium 10%, tartaric acid 20%, sodium bicarbonate 20%, polyvidone 7%, polyethylene glycol 6000 7%, mannitol
15%, lactose 20%, magnesium stearate 1%.
4. the preparation method for diclofenac potassium effervescent tablet of the house pet described in any one of claims 1 to 3, the following institute of step
State:
Diclofenac potassium, tartaric acid, sodium bicarbonate, polyethylene glycol 6000, mannitol, lactose are crossed respectively 80 mesh sieves, the most all
Even mixing, forms mixture of powders；
Polyvidone is dissolved in the ethanol solution that concentration is 95% formation polyvidone ethanol solution, is the most uniformly sprayed onto described
Mixture of powders is made soft material；
Described soft material is carried out pelletize process, obtains soft material granule；At 40～50 DEG C, described soft material granule is carried out drying and processing,
It is then passed through 16 mesh sieves and granulate processes, obtain the soft material granule after granulate；
Soft material granule after described granulate adds magnesium stearate, and uniformly mixes, be then placed in tabletted in tablet machine,
Obtain described diclofenac potassium effervescent tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610361323.2A CN105997921A (en) | 2016-05-27 | 2016-05-27 | Diclofenac potassium effervescent tablet for pets and preparation method of diclofenac potassium effervescent tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610361323.2A CN105997921A (en) | 2016-05-27 | 2016-05-27 | Diclofenac potassium effervescent tablet for pets and preparation method of diclofenac potassium effervescent tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105997921A true CN105997921A (en) | 2016-10-12 |
Family
ID=57094497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610361323.2A Pending CN105997921A (en) | 2016-05-27 | 2016-05-27 | Diclofenac potassium effervescent tablet for pets and preparation method of diclofenac potassium effervescent tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105997921A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112641850A (en) * | 2021-01-05 | 2021-04-13 | 锦州医科大学 | Preparation method of large baical skullcap root fish compound traditional Chinese medicine effervescent tablet |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MC200018A1 (en) * | 1999-09-30 | 2001-03-28 | Setex Sam | Process for the preparation of a drug based on Diclofenac Sodic + vitamin C in liquid solution in the form of an effervescent tablet |
| CN102133206A (en) * | 2011-03-21 | 2011-07-27 | 郑州百瑞动物药业有限公司 | Oxytetracycline hydrochloride effervescent tablet for dairy cattle and preparation method thereof |
| WO2013052019A1 (en) * | 2011-08-19 | 2013-04-11 | Mahmut Bilgic | Production method for effervescent formulations comprising diclofenac |
-
2016
- 2016-05-27 CN CN201610361323.2A patent/CN105997921A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MC200018A1 (en) * | 1999-09-30 | 2001-03-28 | Setex Sam | Process for the preparation of a drug based on Diclofenac Sodic + vitamin C in liquid solution in the form of an effervescent tablet |
| CN102133206A (en) * | 2011-03-21 | 2011-07-27 | 郑州百瑞动物药业有限公司 | Oxytetracycline hydrochloride effervescent tablet for dairy cattle and preparation method thereof |
| WO2013052019A1 (en) * | 2011-08-19 | 2013-04-11 | Mahmut Bilgic | Production method for effervescent formulations comprising diclofenac |
Non-Patent Citations (2)
| Title |
|---|
| BHARAT W. TEKADE ET AL.: "Formulation and evaluation of diclofenac sodium effervescent tablet", 《INNOVATIONS IN PHARMACEUTICALS AND PHARMACOTHERAPY》 * |
| G RAJALAKSHMI ET AL.: "4.Formulation and evaluation of diclofenac potassium effervescent tablets", 《INTERNATIONAL JOURNAL OF PHARMACEUTICAL & BIOMEDICAL RESEARCH》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112641850A (en) * | 2021-01-05 | 2021-04-13 | 锦州医科大学 | Preparation method of large baical skullcap root fish compound traditional Chinese medicine effervescent tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104510717B (en) | Olanzapine orally-disintegrating tablet and preparation method thereof | |
| CN109152740A (en) | The purposes in mostly dynamic obstacle (ADHD) that a kind of 5-(4-chlorophenyl)-2,5-dihydro-3H-imadazo[2,1-a is to release/extended release layered tablet and its in treatment attention missing/ | |
| CN105997921A (en) | Diclofenac potassium effervescent tablet for pets and preparation method of diclofenac potassium effervescent tablet | |
| RU2423981C2 (en) | Pharmaceutical composition for treating parkinson's disease | |
| WO2013026270A1 (en) | Use of dexibuprofen levocetirizine double-layer sustained release tablet in treatment of airway inflammation | |
| JP2022507646A (en) | Uses of braiaconitine A | |
| US11160814B1 (en) | Methods of treatment for disease from coronavirus exposure | |
| CN114225006A (en) | Application of brown adipocyte secretory peptide in prevention and treatment of hypothermia diseases | |
| CN110840875B (en) | Application of borneol cinnamate in preparing medicine for treating hyperplasia of mammary glands | |
| JP7335954B2 (en) | Use of bald head saponin B4 in medicine for anti-acute gouty arthritis | |
| CN104161763A (en) | Application of pharmaceutical compositions in treatment of eczematous dermatitis | |
| CN105287422A (en) | Alfuzosin hydrochloride sustained release tablets and preparation method thereof | |
| CN104352469A (en) | Desvenlafaxine succinate sustained-release tablets and preparation method thereof | |
| CN106540119B (en) | Its pharmaceutical composition of compound wood Ni Zi is preparing the purposes in analgesic | |
| CN100493501C (en) | Scopolamine hydrobromide dry powder inhalant for nose and preparing method | |
| EA032116B1 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| CN111184762A (en) | Solid preparation for cocktail therapy | |
| CN101108170A (en) | Aceclofenac in extended-released tablets and method of manufacturing the same | |
| CN103830393A (en) | Stable curcumin health-care composition | |
| CN102908328A (en) | Fudosteine composition tablet and preparation method thereof | |
| KR101470282B1 (en) | Pharmaceutical Composition comprising a combination of a salt and sugar for proventing or treating lax vagina syndrome or colpoxerosis disease and the use thereof | |
| Kendall et al. | Using the Slug Mucosal Irritation assay to investigate the tolerability of tablet excipients on human skin in the context of the use of a nipple shield delivery system | |
| CN1193777C (en) | Chinese medicine for curing cold by omphalotherapy and its preparing process | |
| CN102552440A (en) | Anti-asthmatic and anti-inflammatory medicament and preparation method and application thereof | |
| CN108125908A (en) | A kind of Montelukast Sodium nose solution and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161012 |
|
| RJ01 | Rejection of invention patent application after publication |